American Society of Hematology

Friday Satellite Symposia

The Friday Satellite Symposia (FSS) are industry-sponsored, CME-certified symposia that are offered the day preceding the ASH annual meeting. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.

The 2018 FSS will take place on Friday, November 30, 2018, in San Diego, California. Please review the official FSS guidelines to learn about hosting a symposium.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

For more information, contact ASH Corporate Relations Coordinator Thelma Barnett at tbarnett@hematology.org.


Clinical and Laboratory Diagnosis of Red Blood Cell Disorders: A Case-Based Algorithmic Approach

November 30, 2018
7:00 a.m. - 11:00 a.m.

MM - Grand Ballroom Salons 10-13

The unmet need in the diagnosis and management of non-malignant hematologic disorders has long been recognized by the American Society of Hematology; and the anticipated shortage of non-malignant hematologists is, in part, due to evolving career choices of fellows focusing on solid tumor oncology. A recent needs assessment reveals that up to 35 percent of respondents desire non-malignant hematology topics. In response to feedback and in collaboration with faculty members from Mayo Clinic?s Division of Hematology, five topics were chosen for this symposium on the value-based, cost-effective laboratory testing on red blood cell (RBC) disorders. Using a case-based approach, the overall objective is to provide an update on interpretation and optimal application of standard and evolving test repertoire to diagnosis of RBC disorders. Combining the clinical and laboratory experience of our faculty, we will illustrate the practical application of testing algorithms derived from the Mayo Clinic practices and illustrate how unnecessary, redundant, and costly laboratory tests can be eliminated while maintaining the highest quality medical care.

Chair:

Rajiv Pruthi, MBBS
Mayo Clinic
Rochester, MN, United States

Speakers:

James Hoyer, MD
Mayo Clinic
Rochester, MN, United States

Ronald Go, MD
Mayo Clinic
Rochester, MN, United States

Jeffrey Winters, MD
Mayo Clinic
Rochester, MN, United States

Jennifer Oliveira, MD
Mayo Clinic
Rochester, MN, United States

Maria Alice Willrich, PhD
Mayo Clinic
Rochester, MN, United States

Contact:

Heidi Zunker
Email: zunker.heidi@mayo.edu

Emerging Role of Immune Checkpoint Blockade in the Treatment of Refractory/Relapsed Hodgkin and Non-Hodgkin Lymphoma

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 1AB

This 1.5-hour, case-based educational program will focus on the emerging role of immune checkpoint blockade in the treatment of refractory/relapsed Hodgkin and non-Hodgkin lymphoma. Participants will have the ability to create their own personalized clinical practice posters before or after the learning session.

Contact:

John Guerriero
Email: john.guerriero@medlearninggroup.com

Evaluation and Treatment of Complement-Mediated Blood Disorders in Women of Childbearing Age

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 7 AB

The complement system is an under-appreciated pathogenic mechanism for thrombotic and inflammatory disorders, with significant cross talk between complement, coagulation, and fibrinolytic systems. Several hematologic diseases are or may be complement-mediated diseases. These include atypical hemolytic uremic syndrome (aHUS); paroxysmal nocturnal hemoglobinuria (PNH); antiphospholipid syndrome (APS); hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome; and thrombotic thrombocytopenic purpura (TTP). Given the rarity of these syndromes, hematologists and obstetricians alike have a limited understanding of complement?s role in these diseases or emerging therapies directed at complement pathways. This exciting symposium brings together leading experts in the field to review the complement physiology with an emphasis on the intersection of complement, coagulation, and diseases affecting reproductive aged or pregnant women. The faculty will provide a comprehensive review of these topics, as well as current diagnostic and treatment strategies for women that can lead to improved care for women of child-bearing age. Issues and questions from the audience will also be addressed.

Chair:

Gowthami Arepally, MD
Duke University Medical Center
Durham, NC, United States

Co-Chair:

Ravindra Sarode, MD
UT Southwestern Medical Center
Dallas, TX, United States

Speakers:

Sanjay Khandelwal, PhD
Duke Medical Center
Durham, NC, United States

Carla Nester, MD
University of Iowa
Iowa City, IA, United States

Charles Parker, MD
University of Utah School of Medicine
Salt Lake City, UT, United States

Ware Branch, MD
University of Utah, Intermountain Healthcare
Salt Lake City, UT, United States

Arthur Jason Vaught, MD
Johns Hopkins School of Medicine, The Johns Hopkins Hospital
Baltimore, MD, United States

Contact:

Melanie Croce-Galis
Email: mcrocegalis@fwgbd.org

Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 31ABC

The recent validation of Bruton?s tyrosine kinase (BTK) inhibition in the management of B-cell non-Hodgkin lymphomas (NHLs) offers clinicians and patients an effective therapeutic option for multiple treatment settings (i.e., earlier treatment phase and patients with high-risk cytogenetics, among others) across diverse disorders such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstr?m macroglobulinaemia, follicular lymphoma, diffuse large B-cell lymphoma, and marginal zone lymphoma. Moreover, ongoing research is investigating rationally-designed BTK inhibitor-based combination approaches in previously-treated and treatment-na?ve patients to improve outcomes. Selecting the right patient for BTK inhibitor therapy should be informed by current evidence, as well as disease subtype, treatment history, and prognostic factors. This PeerView Live CME-certified NHL event, conducted in a "Master Class" case format, will feature multiple expert perspectives on the science that has validated the use of BTK inhibitors in the modern NHL treatment paradigm, providing practical implications of key data, including innovative combinations, and insight on how to best bridge the divide between clinical research and daily practice. The panel of experts will share patient cases and link treatment decisions to application of the most recent, relevant evidence on BTK inhibition in the management of B-cell malignancies, including in the context of clinical trial enrollment.

Chair:

Andre Goy, MD
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, NJ, United States

Speaker:

Michael Wang, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Contact:

Cassie Rametta
Email: cathleen.rametta@peerview.com

How I Treat Acute Lymphocytic Leukemia: Insight From the Experts

November 30, 2018
7:00 a.m. - 11:00 a.m.

MM - Grand Ballroom Salons 1-4

Although outcomes for adolescent, young adult, and adult patients with acute lymphocytic leukemia (ALL) have improved substantially, overall outcomes continue to lag behind the pediatric population. This is due to a variety of factors, including the heterogeneity of presentation and disease course, lower tolerance for aggressive multiagent chemotherapy that incorporates asparaginase, and the propensity for older patients to present with high-risk features for relapse, such as abnormal cytogenetics and presence of the Philadelphia chromosome (Ph). The need for newer therapies in patients who relapse has driven a major surge of innovation in ALL therapy, as the treatment armamentarium has recently expanded to include novel targeted and immunologic therapies offering unprecedented benefit. However, these innovations have also substantially increased the complexity of managing a malignancy with one of the most complicated standard regimens in oncology. This places pressure on clinicians to keep pace with best practices for risk assessment and treatment selection. This symposium is designed to present the critical factors underpinning current treatment recommendations and emerging strategies for clinicians. Through combination of presentations on clinical trial data and current best practices with case scenarios, participants in this activity will gain insight into the cutting edge of ALL management.

Chair:

Stephen Sallan, MD
Dana-Farber Cancer Institute
Boston, MA, United States

Speakers:

David Marks, MB, BS, PhD
Stanford University
Stanford, CA, United States

Dan Douer, MD
USC Norris Comprehensive Cancer Center
Los Angeles, CA, United States

Marlise Luskin, MD, MSCE
Dana-Farber Cancer Institute
Boston, MA, United States

Integration of Immunotherapy Into Treatment for Hematologic Malignancies

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 30

This symposium will directly address the most relevant information available at the time of the presentation with regard to:
  • The present and future of CAR T-cell therapies
  • Immunotherapeutic approaches for multiple myeloma
  • Precision medicine and immunotherapy for acute leukemias
  • Neoantigen applications for hematologic malignancies
  • Immunotherapeutic approaches for lympohoma

Chair:

Helen Heslop, MD, DSc
Texas Children's Hospital
Houston, TX, United States

Speakers:

Carl June, MD
University of Pennsylvania
Philadelphia, PA, United States

Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Ronald Levy, MD
Stanford University School of Medicine
Stanford, CA, United States

Yi Lin, MD, PhD
Mayo Clinic
Rochester, MN, United States

Catherine Wu, MD
Dana-Farber Cancer Institute
Boston, MA, United States

Contact:

Cherie Haley
Email: chaley@rmei.com

Making Strides in the Treatment of B-Cell Malignancies: Keeping Up With New Data and Practice Recommendations

November 30, 2018
7:00 a.m. - 11:00 a.m.

MM - Grand Ballroom Salons 8-9

Malignancies arising from B cells comprise a diverse range of hematologic cancers, including chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma (e.g., follicular lymphoma, marginal-zone lymphoma), and aggressive non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma, mantle cell lymphoma). These different B-cell malignancies carry different prognoses and standards of care, but research over the past decade has led to remarkable progress in the development of targeted and immunologic therapies. Now, clinicians have access to an increasingly wide variety of treatment options for these forms of lymphoma. These options range from B-cell receptor pathway signaling inhibitors targeting Bruton?s tyrosine kinase (Btk) and PI3K-delta, to inhibitors of antiapoptotic regulators, to next-generation antibodies that provide a focus for the immune system to engage an antitumor response. Given the rapid pace and the increasing number of agents available, clinicians need guidance in assessing these new and emerging agents for safety and efficacy, side effects, off-target activity, and clinical trials results. The in-depth presentations will include supporting clinical trial data review, discussion on the elements of treatment selection, and liberal use of case discussion and other interactivity elements.

Chair:

Richard Fisher, MD
Fox Chase Cancer Center, Temple Health
Philadelphia, PA, United States

Speakers:

Simon Rule, MD
Plymouth University
Plymouth, United Kingdom

Jacqueline Barrientos, MD
Northwell Health
Lake Success, NY, United States

John Seymour, MBBS, PhD
Peter Maccallum Cancer Centre
Melbourne, Australia

Nina Wagner-Johnston, MD
Johns Hopkins Hospital
Baltimore, MD, United States

Contact:

Emily Simpson, Prime Oncology
Phone: +1 678 686-7762
Email: Emily.simpson@prIMEoncology.org

Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies

November 30, 2018
7:00 a.m. - 11:00 a.m.

Omni - Omni Grand BR ABCDE

The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present this symposium. This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Chair:

Matt Kalaycio, MD
Cleveland Clinic Foundation
Cleveland, OH, United States

Speakers:

Steven Gore, MD
Yale Cancer Center
New Haven, CT, United States

Matt Kalaycio, MD
Cleveland Clinic Foundation
Cleveland, OH, United States

Luca Malcovati, MD
University of Pavia Medical School
Pavia, Italy

John Mascarenhas, MD
Mount Sinai School of Medicine
New York, NY, United States

Jae Park, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Jamile Shammo, MD
Rush University Medical Center
Chicago, IL, United States

Contact:

Ronna Romano
Email: romanor@ccf.org

The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care

November 30, 2018
7:00 a.m. - 11:00 a.m.

MM - Grand Ballroom Salons 5-6

Although outcomes for adult patients diagnosed with acute lymphocytic leukemia (ALL) have improved substantially, they continue to lag behind the pediatric population.?This is due to a variety of factors, including the heterogeneity of presentation and disease course, lower tolerance for aggressive multi-agent chemotherapy, and the propensity for older patients to present with high-risk features for relapse, such as abnormal cytogenetics and presence of the Philadelphia chromosome (Ph).?The need for newer therapies in patients who relapse has driven a major surge of innovation in ALL therapy, as the treatment armamentarium has recently expanded to include novel targeted and immunologic therapies offering unprecedented benefit. However, the increasing number of treatment options has also substantially increased the complexity of managing a malignancy with one of the most complicated standard regimens in oncology.?This program?s in-depth presentations include?risk assessment (patient and disease characteristics); the role of MRD; treatment selection in patient populations with notably poor prognosis, such as elderly patients; Ph-positive disease; and relapsed/refractory disease. Case scenarios will be used liberally throughout the activity to allow full discussion and application. Participants in this activity will gain insight into the cutting edge of ALL management.

Chair:

Martin Tallman, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Speakers:

Anthony Selwyn Stein, MD
City of Hope Medical Center
Duarte, CA, United States

Steven Coutre, MD
Stanford University School of Medicine
Stanford, CA, United States

Richard Stone, MD
Dana-Farber Cancer Institute
Boston, MA, United States

Nicholas Short, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Contact:

Emily Simpson, Prime Oncology
Phone: +1 678 686-7762
Email: Emily.simpson@prIMEoncology.org

The Evolution of Multiple Myeloma Patient Management: Managing Today and Preparing for Tomorrow

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 6 CF

The multiple myeloma (MM) arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope but presents new challenges. Some patients enjoy many years in clinical remission, whereas for others survival is no more than three years. This reflects the heterogeneity of MM and underscores the inappropriateness of a one-size-fits-all treatment approach. Improving outcomes requires building on the foundation of current MM therapies with new agents and combinations, and it requires better understanding the nature of the disease to provide patients with a more personalized approach to treatment. Oncology clinicians have a growing array of tools to favorably influence a patient?s quality of life, but clinicians can only take advantage of those tools by remaining current on the latest research and understanding the appropriate timing and strategies for using newer therapies. This symposium will consist of evidence-based presentations interspersed with patient cases designed to reinforce key points. The cases will help learners integrate new information and strategies into their practices and better enable them to assess such factors as patient profile, clinical evidence, and risk-versus-benefit in the quest to achieve the best possible durable response. iPad technology will also be used.

Chair:

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA, United States

Speakers:

Keith Stewart, MBChB, MBA
Mayo Clinic
Scottsdale, AZ, United States

Ajai Chari, MD
Mt. Sinai School of Medicine
New York, NY, United States

Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Maria-Victoria Mateos, MD, PhD
University Hospital of Salamanca
Salamanca, Spain

Gregory Orloff, MD
Virginia Cancer Specialists
Fairfax, VA, United States

Contact:

Karen Tenaglia
Email: ktenaglia@redmeded.com

Translating Pathophysiological Advances Into Innovative Treatments for Myelodysplastic Syndromes and Related Myeloid Neoplasms

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 6 A

This symposium will describe recent advances in our understanding of the pathophysiology of myelodysplastic syndromes and related myeloid neoplasms, as well as how these advances are being translated into more effective treatments for these patients.

Chair:

Mario Cazzola, MD
University of Pavia
Pavia, Italy

Speakers:

Elsa Bernard, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Michael Heuser, MD
Hannover Medical School
Hannover, Germany

Matthew Walter, MD
Washington University in St. Louis
St. Louis, MO, United States

Michael Savona, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN, United States

Ghulam Mufti, DM
King's College London
London, United Kingdom

Contact:

Lea Harrison
Email: lharrison@mds-foundation.org

Untangling Amyloidosis 2018

November 30, 2018
7:00 a.m. - 11:00 a.m.

SDCC - Room 28 A-D

This CME symposium will consist of a series of presentations focusing on diagnosis, risk stratification, and treatment of systemic amyloidosis, with a particular emphasis on AL amyloidosis. The first three invited speakers will each briefly present an AL patient case vignette, which raises questions or illustrates key clinical management points related to the assigned topic. The second three speakers will focus on recent advances in the therapy of AL and other types of amyloidosis (such as ATTR), including sessions on emerging anti-fibril antibodies, gene-silencing, and protein conformational stabilizer therapies. Given the importance of multidisciplinary management of amyloidosis, we intend to live-stream the presentations to expand the audience beyond those attending the ASH annual meeting. The program is intended to be interactive, and the audience will be asked to provide opinions and answers to questions intermittently throughout the program via an iPad-based system. Social media will be used in real time to broadcast content and generate discussion. There will be a 20-minute panel discussion following the presentations, during which time live audience and web-based questions can be posed and answered. Enduring web-based content derived from the live symposium will be made available subsequent to the program.

Chair:

Jeffrey Zonder, MD
Karmanos Cancer Institute
Detroit, MI, United States

Speakers:

Giovanni Palladini, MD, PhD
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy

Suzanne Lentzsch, MD, PhD
Columbia University
New York, NY, United States

Ashutosh Wechalekar, MBBS, DM
University College London Medical School Royal Free Campus
London, United Kingdom

Jeffrey Zonder, MD
Karmanos Cancer Institute
Detroit, MI, United States

Teresa Coelho, MD
Hospital Santo Ant?nio
Porto, Portugal

John Berk, MD
Boston University School of Medicine
Boston, MA, United States

Contact:

Jeffrey Zonder
Email: zonderj@karmanos.org

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)

November 30, 2018
12:30 p.m. - 4:30 p.m.

Grand Hyatt - Harbor Ballroom

This activity, the first of a proposed two-part series, will attempt to address many of the most common practical issues encountered by clinicians managing patients with Hodgkin and non-Hodgkin lymphomas as well as chronic lymphocytic leukemia (CLL). To accomplish this goal, prior to the event RTP will recruit six general hematologic oncologists to serve as the project?s planning committee. These individuals will participate in a closed planning session at RTP headquarters, during which they will discuss a number of key questions, issues, and challenging cases from their own practices. This information will provide the basis for the agenda. The meeting, which will feature five renowned investigators serving as the faculty, will employ a blend of short didactic presentations, interactive audience polling using networked iPads, and extensive moderated panel discussion. The panel discussion will provide perspectives on new and emerging research and will address many of the real-world concerns voiced by the planning committee. A video-recorded capture of the program will be distributed as an enduring CME activity in order to deliver the valuable and practical information from the symposium to a larger, worldwide audience.

Chair:

Neil Love, MD
Research To Practice
Miami, FL, United States

Speakers:

Martin Dreyling, MD, PhD
University Hospital, Ludwig Maximilian University of Munich
Munich, Germany

Jonathan Friedberg, MD, MMSc
University of Rochester
Rochester, NY, United States

Brad Kahl, MD
Washington University School of Medicine in St. Louis
St. Louis, MO, United States

Sonali Smith, MD
The University of Chicago
Chicago, IL, United States

Michael Williams, MD
University of Virginia School of Medicine
Charlottesville, VA, United States

Contact:

Brian Moss
Email: meetings@researchtopractice.com

Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds

November 30, 2018
12:30 p.m. - 4:30 p.m.

Manchester Grand Hyatt - Grand Hall D

Participants of this educational curriculum will be brought up to date on the most recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies that will potentially impact treatment and management of patients with acute and chronic graft-versus-host disease. The symposium is designed to educate audiences in an innovative, engaging format and will include a mix of didactic lecture, case-studies that reflect challenges among community hematologists when deciding clinical trial options for patients, panel discussion, and Q&A. The program is designed to be fast-paced and highly interactive between the faculty and audience. Case studies and panel discussions will be used by the chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Corey Cutler, MD, PhD
Harvard Medical School, Division of Hematologic Oncology, Dana-Farber Cancer Institute
Boston , MA , United States

Speakers:

Shernan Holtan, MD
University of Minnesota
Minneapolis, MN, United States

Corey Cutler, MD, MPH
Dana-Farber Cancer Institute
Boston, MA, United States

David Miklos, MD, PhD
Stanford University School of Medicine
Stanford, CA, United States

Contact:

Dayna Kleinstein, Physicians’ Education Resource
Phone: 609-325-4864
Email: Dkleinstein@gotoper.com

Advancing Polycythemia Vera and Myelofibrosis: An Expert Tumor Board Discussion

November 30, 2018
12:30 p.m. - 4:30 p.m.

MM - Grand Ballroom Salons 5-6

This activity will bring together renowned international experts in myeloproliferative neoplasm (MPN) treatment and clinical research for an in-depth mock tumor board that will assess the clinical impact of recent and emerging trial data in polycythemia vera and myelofibrosis. A series of case presentations will be presented with clinical trial data tightly integrated to illuminate MPN treatment decisions related to front-line and beyond therapies, sequencing, switching, and patient and disease characteristics. Adverse events and management will be educationally tied to appropriate presentations. Future directions in the field will also be addressed and considered with regard to how recent developments and highly anticipated trials may shape care in the near future. Faculty will be present onstage throughout the program. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.

Chair:

Brady Stein, MD
Northwestern University
Chicago, IL, United States

Speakers:

Ronald Hoffman, MD
Mount Sinai School of Medicine
New York, NY, United States

Michael Mauro, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Nicolaus Kroeger, MD
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Contact:

Dayna Kleinstein, Physicians? Education Resource
Phone: 6093254681
Email: DKleinstein@gotoper.com

Advancing the Treatment of Hemoglobinopathies: Gene Therapy for Beta Thalassemia and Sickle Cell Disease

November 30, 2018
12:30 p.m. - 4:30 p.m.

Omni - Omni Grand BR ABCDE

Significant morbidity accompanied by limited treatment options have rendered the hemoglobinopathies particularly challenging to clinicians treating patients with these disorders. Recently, gene therapy has begun to emerge as a potential treatment option for both beta thalassemia and sickle cell disease. In this program, experts in the field will explore ongoing advances in gene therapy technology, the genetic mutations and pathophysiology of beta thalassemia and sickle cell disease that make a gene therapy approach feasible, and the latest clinical data from gene therapy options in development.

Chair:

David Williams, MD
Dana-Farber/Boston Children?s Cancer and Blood Disorders Center
Boston, MA, United States

Speakers:

Alessandra Biffi, MD
Dana-Farber/Boston Children?s Cancer and Blood Disorders Center
Boston, MA, United States

Mark Walters, MD
UCSF Benioff Children's Hospital Oakland
Oakland, CA, United States

Contact:

Amy Cramer
Email: acramer@medscape.net

D is for Diagnosis: Solving the Mystery of Rare Hematologic Disorders

November 30, 2018
12:30 p.m. - 4:30 p.m.

MM - Grand Ballroom Salons 1-4

This program will discuss the latest data, share perspectives and best practices, and forecast applications of key clinical challenges and questions regarding identification of rare hematologic disorders. The importance of differential diagnosis when treating patients who present with hematologic symptoms of unknown origin will also be discussed. With the help of expert faculty, PER will challenge the audience to play the role of the detective as they approach each patient case to ultimately uncover the underlying disease at play. Audience members will be encouraged to look for clues as they diagnose each patient, similar to how a detective would solve a case. The symposium will consist of a mix of didactic lecture and ?mystery? case studies that reflect challenges among community oncologists/hematologists, in addition to panel discussion and Q&A. The program is designed to take an investigational approach to treating rare hematologic diseases and will encourage interaction between faculty and audience. Case studies and panel discussions will be used by the chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Pramod Mistry, MD, PhD
Yale University
New Haven , CT , United States

Speaker:

Pramod Mistry, MD, PhD
Yale University
New Haven, CT, United States

Contact:

Dayna Kleinstein, Physicians Education Resource
Phone: (609) 325-4864
Email: DKleinstein@gotoper.com

Differentiating Diagnosis and Treatment to Fit the Patient With Hemolytic Anemia: A Case-Based Approach

November 30, 2018
12:30 p.m. - 4:30 p.m.

MM - Grand Ballroom Salons 10-13

Participants of this educational curriculum will be brought up to date on the most recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies that will potentially impact treatment and management of patients with hemolytic anemias. The symposium is designed to educate audiences in an innovative, engaging format and will include a mix of didactic lecture, case-studies that reflect challenges among community hematologists when deciding clinical trial options for patients, panel discussion, and Q&A. The program is designed to be fast-paced and highly interactive between the faculty and audience. Case-studies and panel discussions will be used by the chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Rachael Grace, MD

Boston, MA, United States

Speakers:

Uwe Platzbecker, MD
Professor of Translational Hematology, Department of Internal Medicine, Head, Section of Hematology, University Hospital Carl Gustav Carus
Dresden, Germany

Janet Kwiatkowski, MD, MSCE
Children's Hospital of Philadelphia
Philadelphia, PA, United States

Sujit Sheth, MD
Weill Cornell Medical College
New York, NY, United States

Contact:

Dayna Kleinstein, Physicians Education Resource
Phone: 6093254864
Email: DKleinstein@gotoper.com

Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes

November 30, 2018
12:30 p.m. - 4:30 p.m.

SDCC - Room 30

CAR T cells have emerged as a highly effective therapy in patients with lymphoma and myeloma. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these hematologic malignancies need expert guidance to evaluate clinical data of CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available. This interactive satellite symposium will evaluate the latest data of CAR T-cell therapies approved or under investigation in patients with lymphoma, myeloma, and leukemia. The symposium will provide expert interpretation of emerging data and guidance regarding its application in practice. There will also be an associated online enduring activity titled, ?Expert Insights.? This 20-minute, videotaped discussion between the symposium chair and one to two faculty experts will highlight and summarize the most clinically relevant data from the symposium. There will be an additional archived webcast and downloadable slides.

Chair:

David Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Speakers:

Julie Vose, MD
Univeristy of Nebraska
Omaha, NE, United States

Sattva Neelapu, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Shannon Maude, MD, PhD
Children's Hospital of Philadelphia
Philadelphia, PA, United States

James Kochenderfer, MD
National Cancer Institute Center for Cancer Research
Bethesda, MD, United States

Contact:

Chloe Dunnam
Email: dunnam@bioascend.com

Managing Multiple Myeloma: What's Next?

November 30, 2018
12:30 p.m. - 4:30 p.m.

SDCC - Room 28 A-D

The goal of this initiative is to improve the knowledge of hematologists/oncologists about agents with novel mechanisms of action that are in development for the management of multiple myeloma (MM). Emerging agents to be discussed are BCMA targeted therapy, CD38 targeted therapy, small molecule inhibitors targeting XPO1 and BCL-2, and targets of the future (e.g., CD33, CD138, AKT, RAS, and epigenetic approaches).?For each target, the mechanism of action, rationale for drug target in MM, proof of concept, safety/efficacy data, ongoing clinical trials, and potential role in the MM treatment paradigm will be presented. Additionally, the expert panel will discuss the impact of these novel therapies on the clinical paradigm.

Chair:

Thomas Martin, MD
University of California
San Francisco, CA, United States

Speakers:

Jonathan Kaufman, MD
Emory University School of Medicine
Atlanta, GA, United States

Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Boston, MA, United States

Thomas Martin, MD
San Francisco, CA, United States

Thomas Martin, MD
University of California
San Francisco, CA, United States

Contact:

Charlene Foroutan
Email: cforoutan@medscape.net

Medical Crossfire®: How the Experts Treat Acute Lymphocytic Leukemia: Case Discussions From Adolescent to Adult

November 30, 2018
12:30 p.m. - 4:30 p.m.

MM - Grand Ballroom Salons 8-9

This live satellite symposium will discuss the latest data, share perspectives and best practices, and forecast applications of key clinical challenges and questions regarding the treatment in acute lymphocytic leukemia (ALL). The symposium is designed to educate audiences in an engaging format and will include a mix of Medical Crossfire? questions and audience Q&A portions that reflect challenges among community hematologists. The program is designed to be fast-paced and highly interactive between faculty and audience. "How I Treat" case-studies and panel discussions will be used by the chair to challenge faculty on their treatment decisions. Audience members will also have the opportunity to reflect on best practices and their own clinical decisions for higher educational engagement. Medical Crossfire? is based on the understanding that exposure to differing?and sometimes provocative?opinions, insights, and philosophies fuels learning and understanding among health care professionals. With the educational gaps and questions surrounding best practices in the treatment of ALL, educational activities that showcase expert discussions and exchanges of ideas will provide physicians with the opportunity to more deeply understand clinical scenarios where using different therapeutic options to treat ALL will optimize patient outcomes.

Chair:

Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Speakers:

Stephan Grupp, MD, PhD
Children's Hospital of Philadelphia
Philadelphia, PA, United States

Daniel J. DeAngelo, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, United States

Ching-Hon Pui, MD
St. Jude Children's Research Hospital
Memphis, TN, United States

Herve Dombret, MD
Hopital Saint Louis
Paris, France

Contact:

Dayna Kleinstein, Physicians Education Resource
Phone: 6093254864
Email: DKleinstein@gotoper.com

Moving Toward a Cure for More Patients With Hodgkin Lymphoma: Expert Guidance and Practical Case Discussions

November 30, 2018
12:30 p.m. - 4:30 p.m.

Grand Hyatt - Grand B

This symposium is the perfect opportunity for clinicians to learn about the latest therapeutic advances in Hodgkin lymphoma (HL). In the weeks leading up to the symposium, this program will include two online expert commentaries focused on the evolving developments in HL therapy. At the symposium, participants will hear short, focused didactic presentations, followed by a series of case challenges with substantial time specifically devoted to audience and expert panel discussions. Attendees will be able to interact directly with the expert panel through a networked, all-in-one handheld device. This technology will enable a large audience to personally contribute to case discussions and directly text questions and additional case challenges for the panelists to consider. To end the symposium, the faculty will look ahead to promising new agents and future directions that may advance the care of patients with HL. Topics will include initial therapy for early-stage HL, therapy for previously untreated stage III or IV classic HL, using response-adapted treatment prior to ASCT, preventing or delaying second relapse after ASCT, managing late relapse after initial therapy, and therapeutic strategies for disease progression after high-dose chemotherapy and ASCT.

Chair:

Joseph Connors, MD
Centre for Lymphoid Cancer
Vancouver, BC, Canada

Speakers:

Robert Chen, MD
City of Hope
Duarte, CA, United States

Andrew Evens, DO, MSc
Rutgers Cancer Institute of New Jersey / Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ, United States

Contact:

Cco Registration, Clinical Care Options
Phone: 8046908254
Email: Registration@clinicaloptions.com

Moving Towards Precision Therapy for Patients with AML: Clinical Challenges and Future Directions

November 30, 2018
12:30 p.m. - 4:: 00 a.m.

GH - Grand Hall C

Advances in efficacious and better tolerated therapies, plus the development of predictive and prognostic factors, have ushered in a new era of personalized therapy for patients with acute myeloid leukemia (AML). Prior to this live event, the program will include two online expert commentaries focused on the evolving developments in AML therapy. At the live symposium, faculty will focus on the dramatic and rapid changes in AML treatment, including state-of-the-art therapeutics for newly diagnosed AML, advances in antibody?drug conjugates, treatment options for FLT3- or IDH-mutant AML, and reflection on the next frontier in AML care. A moderated panel discussion and an audience question-and-answer session will close each section of the symposium and will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice. Symposium participants will be provided with a networked, all-in-one handheld device that enables those in the audience to fully interact, text, and contribute to the cases discussed by the panel. The symposium will feature relevant treatment decision support tools for AML along with multiple expert consultation resources to help guide practical application of new insights gained during the event.

Chair:

Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Contact:

CCO Meetings , Clinical Care Options
Phone: 8046908254
Email: Meetings@clinicaloptions.com

Navigating Immune Thrombocytopenic Purpura Treatment in 2018: Expert Perspectives on the Latest Advances

November 30, 2018
12:30 p.m. - 4:30 p.m.

GH - Seaport Ballroom EFGH

This event is designed to provide timely, practical, and accessible education on the latest advances and emerging data related to the diagnosis and management of immune thrombocytopenia purpura (ITP). These advances have informed the development of novel agents, and data continue to emerge regarding the treatment and ongoing management of ITP. The expert panel will discuss the pathophysiology of ITP, key features of conventional and newer therapies, emerging treatment approaches, and perspectives on how to optimally incorporate available evidence and newer treatment options into practice. Attendees of the live symposium will engage with expert faculty by participating in case-based dialogue and real-time polling using a proprietary tablet app. Polling results reflect current practice trends and help faculty to frame their responses based on apparent gaps within the context of the most current evidence. iPads will be provided to attendees on site immediately prior to the start of the event.

Chair:

Ivy Altomare, MD
n/a
Durham, NC, United States

Speakers:

Ellis Neufeld, MD
St. Jude Children's Research Hospital
Memphis, TN, United States

Adrian Newland, FRCP
London, United Kingdom

Adrian Newland, FRCP
The Royal London Hospital Pathology and Pharmacy Building
London, United Kingdom

Contact:

Charlene Foroutan
Email: cforoutan@medscape.net

New Strategies for Multiple Myeloma Care: Next Steps for The Future

November 30, 2018
12:30 p.m. - 4:30 p.m.

Grand Hyatt - Seaport Ballroom ABCD

This year?s annual International Myeloma Foundation and Clinical Care Options cosponsored symposium will reveal how experts approach current therapeutic decisions for their patients with myeloma. The symposium will also provide a look ahead at new data and promising agents that may soon change practice. International myeloma experts?Brian G.M. Durie, MD, Shaji Kumar, MD, Philippe Moreau, MD, S. Vincent Rajkumar, MD, and Jes?s F. San-Miguel, MD, PhD?will debate five clinical questions, discuss the available evidence along with the challenges that impact therapeutic decisions, and share their individual treatment recommendations for each case. Throughout the symposium, participants will be able to vote on every case scenario and text questions directly to the panel for their consideration. Discussion topics include: initiation and selection of personalized induction therapy (where we are now); current controversies in the management of the newly diagnosed multiple myeloma patient (where we are going); transplantation, consolidation, and maintenance after induction therapy (where we are now and where we are going); therapeutic strategies for patients with relapsed/refractory disease (where we are now); future directions and promising new agents; and review of a 2019 treatment algorithm for multiple myeloma.

Chair:

Brian Durie, MD
Samuel Oschin Cancer Center Cedars-Sinai
Los Angeles, CA, United States

Speakers:

S. Vincent Rajkumar, MD
Mayo Clinic College of Medicine
Rochester, MN, United States

Shaji Kumar, MD
Mayo Clinic
Rochester, MN, United States

Philippe Moreau, MD
University Hospital of Nante
Nantes, France

Jesus San-Miguel, MD, PhD
Cl?nica Universidad De Navarra
Pamplona, Spain

Contact:

Cco Registration, Clinical Care Options
Phone: 8046908254
Email: Registration@clinicaloptions.com

Old and New Treatments for Sickle Cell Anemia: Is There a Standard of Care?

November 30, 2018
12:30 p.m. - 4:30 p.m.

MM - Marina Ballroom D

Patients with sickle cell anemia develop a wide variety of acute and chronic clinical complications, which lead to serious morbidity and early mortality. In developed countries, transfusions and hydroxyurea are established disease-modifying treatments that are readily available to most patients; stem cell transplantation can be curative, but its access and suitability are relatively limited at the current time. In contrast, in low-resource settings most patients are not identified early in life, and little preventive or medical care is offered. Most patients do not have access to transfusions or hydroxyurea, and many affected children die before age five. Over the past few years, a plethora of new therapeutic options has emerged for sickle cell anemia, some to prevent or ameliorate acute complications and others designed to reduce sickling and hemolytic anemia. How these new therapies fit into current and future treatment paradigms remains unclear. This exciting symposium will bring together leading experts to discuss both old and new treatments for sickle cell anemia. Faculty members from high-resource and low-resource countries will provide their perspectives about what represents standard of care for sickle cell anemia, where the current treatment gaps and challenges lie, and how clinicians can determine the best therapeutic choices for their patients.

Chairs:

Russell Ware, MD, PhD

Cincinnati, OH, United States

Russell Ware, MD, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States

Speakers:

Russell Ware, MD, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States

Mariane De Montalembert, MD
Hospital Necker
Paris, France

Patrick McGann, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States

Biree Andemariam, MD
University of Connecticut Health Center
Farmington, CT, United States

Marvin Reid, MB, BS, PhD
University of the West Indies, Mona
Kingston, Jamaica

Leon Tshilolo, MD, PhD
Monkole Center Hospital
Kinshasa, Congo, Democratic Republic of the

Contact:

Russell Ware
Email: russell.ware@cchmc.org

PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy

November 30, 2018
12:30 p.m. - 4:30 p.m.

SDCC - Room 6 CF

The goal of this activity is to improve knowledge of the role of PI3 kinase inhibitors in the management of non-Hodgkin lymphoma and to improve competence in the use of PI3 kinase inhibitors in practice. Topics include the rationale for targeting the PI3 kinase signaling pathway, the differences between the available agents, and clinical trial data regarding the efficacy and safety of those agents.

Chair:

Richard Furman, MD
Weill Cornell Medical College
New York, NY, United States

Speakers:

Martin Dreyling, MD, PhD
University Hospital, Ludwig Maximilian University of Munich
Munich, Germany

Ian Flinn, MD, PhD
Sarah Cannon Research Institute
Nashville, TN, United States

Contact:

Charlene Foroutan
Email: cforoutan@medscape.net

Protecting Our Vulnerable, Medically Ill Patients From Venous Thromboembolism

November 30, 2018
12:30 p.m. - 4:30 p.m.

SDCC - Room 7 AB

This CME symposium is designed to familiarize clinicians with the latest strategies to prevent venous thromboembolism in the hospital setting. Attendees of this live symposium will interact with a panel of expert faculty by participating in a question-and-answer session, case dialogue, and polling using interactive tablet technology. Live engagement will allow for the exchange of ideas, deepening participant involvement and enabling attendees to drive the discussion based on their own clinical challenges.

Chair:

Samuel Goldhaber, MD
Brigham and Women's Hospital
Boston, MA, United States

Speakers:

Craig Kessler, MD
Georgetown University Medical Center
Washington, DC, United States

Michael Streiff, MD
Johns Hopkins Medical Institutions
Baltimore, MD, United States

Samuel Berkman, MD
University of California
Beverly Hills, CA, United States

Contact:

Kelley Suttenfield
Email: ksuttenfield@medscape.net

Sickle Cell Disease Forum: Innovation in Drug Development and Emerging Science

November 30, 2018
12:30 p.m. - 4:30 p.m.

GH - Grand Hall D

While sickle cell disease (SCD) is a molecularly well-characterized disease, there are few treatments available and less than one-third of eligible patients receive standard of care. Fortunately, recent years have brought an explosion in therapeutic advances regarding the management of patients with SCD, including but not limited to gene therapy, novel drug targets, and new clinically meaningful endpoints. Moreover, an increased understanding of disease state and phenotypes is leading to evolving management recommendations. This engaging two-hour symposium will be led by renowned experts who will discuss these advances and implications for clinical practice.

Chair:

Russell Ware, MD, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States

Speakers:

Mark Walters, MD
UCSF Benioff Children's Hospital Oakland
Oakland, CA, United States

Kenneth Ataga, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Elliott Vichinsky, MD
UCSF Benioff Children's Hospital Oakland
Oakland, CA, United States

Contact:

Kristin Riday
Email: kriday@vindicomeded.com

What Biosimilars Mean for Your Hematology/Oncology Practice

November 30, 2018
12:30 p.m. - 4:30 p.m.

SDCC - Room 6 A

This live symposium will cover background information on biosimilars as well as faculty panel discussions?on the latest developments and considerations surrounding biosimilars in oncology at the point of care. This will be followed by case-based scenarios presented by the faculty, which will?engage learners through a series of interactive questions (?What do YOU know?? and ?What does this mean for YOUR PRACTICE??). The symposium will feature an audience?response system (ARS),?supportive presentations, and a faculty round-table discussion to reinforce learning. It?is designed to equip hematology/oncology clinicians with increased awareness, evidence-based knowledge, and competence regarding biosimilars. Additionally, the symposium aims to ensure clinicians are able to confidently apply that knowledge safely and effectively to practice, as well as answer questions in multiple situations/scenarios.

Chair:

Robert Rifkin, MD
Rocky Mountain Cancer Center
Denver, CO, United States

Speaker:

Corey Cutler, MD, MPH
Dana-Farber Cancer Institute
Boston, MA, United States

Contact:

Kelley Johnson
Email: kjohnson@francefoundation.com

What's New in VTE? Evaluating the Latest Evidence and Grades of Recommendation

November 30, 2018
12:30 p.m. - 4:30 p.m.

Grand Hyatt - Coronado ABC

This CME symposium is designed to familiarize clinicians with the emerging data and management concerns related to management of venous thromboembolism (VTE). Attendees of this live symposium will interact with a panel of expert faculty by participating?in a question-and-answer session, case dialogue, and polling using interactive tablet technology. Live engagement allows for the exchange of ideas, deepening participant involvement and enabling attendees to drive the discussion based on their own clinical challenges.

Chair:

Alok Khorana, MD
Cleveland Clinic
Cleveland, OH, United States

Speakers:

Rupert Bauersachs, MD
Klinikum Darmstadt GmbH
Darmstadt, Germany

Ajay Kakkar, MD, PhD
Thrombosis Research Institute London
London, United Kingdom

Jeffrey Weitz, MD
McMaster University
Hamilton, ON, Canada

Contact:

Kelley Suttenfield
Email: ksuttenfield@medscape.net

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia, and Amyloidosis (Part 2 of a 2-Part Series)

November 30, 2018
6:00 p.m. - 10:00 p.m.

Grand Hyatt - Harbor Ballroom

This activity, the second of a proposed two-part series, will attempt to address many of the most common practical issues encountered by clinicians managing patients with multiple myeloma, including the related diseases Waldenstr?m macroglobulinemia and amyloidosis. To accomplish this goal, prior to the event RTP will recruit six general hematologic oncologists to serve as the project?s planning committee. These individuals will participate in a closed planning session at RTP headquarters, during which they will discuss a number of key questions, issues, and challenging cases from their own practices. With this information providing the basis for the agenda, the meeting, which will feature five renowned investigators serving as the faculty, will employ a blend of short didactic presentations, interactive audience polling using networked iPads, and extensive moderated panel discussion to provide perspectives on new and emerging research and address many of the real-world concerns voiced by the planning committee members. A video-recorded capture of the program will be distributed as an enduring CME activity to deliver the valuable and practical information that emerges to a larger, worldwide audience.

Chair:

Neil Love, MD
Research To Practice
Miami, FL, United States

Speakers:

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, AZ, United States

Sagar Lonial, MD
Winship Cancer Institute
Atlanta, GA, United States

Robert Orlowski, MD, PhD
MD Anderson Cancer Center
Houston, TX, United States

Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Boston, MA, United States

Katja Weisel, MD, PhD
Universitatsklinikum Tubingen
Tubingen, Germany

Contact:

Sylvia Eriksen
Email: meetings@researchtopractice.com

Focus on AML: Clinical Practice Today

November 30, 2018
6:00 p.m. - 10:00 p.m.

Omni - Omni Grand BR ABCDE

This initiative, targeted toward community providers, will use case-based discussion to illustrate recent advances in the diagnosis, characterization, and management of acute myeloid leukemia (AML). The importance of genetic testing and minimal residual disease (MRD) assessment, how to interpret test results, and how to use results to guide therapy will also be discussed. Attendees will interact with a panel of experts by participating in a question-and-answer period, case dialogue, and polling using an audience response system.

Chair:

Gail Roboz, MD
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY, United States

Speakers:

Eytan Stein, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Harry Erba, MD, PhD
University of Alabama at Birmingham
Birmingham, AL, United States

Contact:

Erin Rafferty
Email: erafferty@medscape.net

Hemophagocytic Lymphohistiocytosis: New Treatment Horizons

November 30, 2018
6:00 p.m. - 10:00 p.m.

Grand Hyatt - Coronado ABC

This CME symposium is designed to familiarize clinicians with hemophagocytic lymphohistiocytosis (HLH), including the key diagnostic criteria, underlying disease mechanisms, and current treatment options. The symposium will also introduce emerging clinical trial data, which will impact the management of hemophagocytic lymphohistiocytosis. Attendees of this live symposium will interact with a panel of expert faculty through interactive tablet technology, live polling, and a question-and-answer session. This multimodal method of engagement allows for the exchange of ideas, deepening participant involvement and enabling attendees to drive the discussion.

Chair:

Michael Jeng, MD
Stanford University School of Medicine
Palo Alto, CA, United States

Speakers:

Michael Jordan, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States

Jan-Inge Henter, MD, PhD
Karolinska Hospital
Stockholm, Sweden

Franco Locatelli, Prof
IRCCS Ospedale Pediatrico Bambino Gesu
Rome, Italy

Contact:

Peter Schoonheim
Email: pschoonheim@webmd.net

Hemophilia Perspectives: Current Insights on the Evolution of Gene Therapy

November 30, 2018
6:00 p.m. - 10:00 p.m.

Manchester Grand Hyatt - Grand Hall A

Chair:

Michael Recht, MD, PhD
The Hemophilia Center Oregon Health & Science University
Portland, OR , United States

Speakers:

Gerald Dolan, MD
Guy’s and St Thomas’ Hospital
London, United Kingdom

Katherine Ponder, MD
Washington University School of Medicine
St. Louis, MO, United States

Tammuella Chrisentery Singleton, MD
Tulane University School of Medicine
New Orleans, LA, United States

Contact:

Jodi Andrews
Email: jandrews@conceptsinmed.com

Insights Into Anemia in Chronic Kidney Disease and Beyond: New Discoveries, Strategies, and Models of Care

November 30, 2018
6:00 p.m. - 10:00 p.m.

MM - Marina Ballroom D

Anemia is one of the many serious consequences of chronic kidney disease (CKD) that often goes unrecognized and undertreated, leaving patients with low quality of life and at risk for increased morbidity and mortality. For many years, the standard treatment for anemia in CKD has been erythropoiesis-stimulating agents (ESAs) with iron; however, the full correction of hemoglobin with ESAs has been called into question due to safety concerns. Fortunately, new insights into the pathophysiology of anemia have revealed novel treatment targets that may overcome the limitations associated with ESA use. Increased understanding of hepcidin and hypoxia-inducible factor in anemia has led to the development of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). These oral small molecules have demonstrated hemoglobin correction with lower peak serum erythropoietin levels and good overall tolerability. HIF-PHIs are currently being investigated for the treatment of anemia in CKD, myelodysplastic syndromes (MDS) and other disease states. This ACCME/ANCC/ACPE/AAPA-accredited symposium will provide expert insights into emerging therapies for anemia management in CKD and MDS. An interprofessional faculty panel will explore the latest clinical trial data for HIF-PHIs and discuss how these novel agents compare to ESAs, biosimilars, and other therapies for anemia management.

Chair:

David Henry, MD
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, PA, United States

Speakers:

Jeffrey Berns, MD
Hospital of the University of Pennsylvania
Philadelphia, PA, United States

Wendy St. Peter, PharmD
University of Minnesota
Minneapolis, MN, United States

John Glaspy, MD, MPH
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA, United States

Ajay Singh, MBBS, MBA
Harvard Medical School
Boston, MA, United States

Contact:

Rebecca Weaver
Email: rweaver@ceconcepts.com

Novel Therapies for AML: Expanding Future Options

November 30, 2018
6:00 p.m. - 10:00 p.m.

GH - Seaport Ballroom EFGH

The goal of this initiative is to improve the knowledge of hematologists/oncologists about emerging novel therapies in late-stage development for the treatment of acute myeloid leukemia (AML).?Agents covered will include FLT3 inhibitors (quizartinib, Crenolanib, gilteritinib, sorafenib), novel small molecule inhibitors (venetoclax, alvocidib), epigenetic modifiers (guadecitabine, pracinostat), and radioimmunotherapy (131I-apamistamab).?The mechanism of actions, safety/efficacy data, and role in AML treatment paradigm will be discussed.?The expert panel will discuss challenges in AML and potential benefits of newer agents.

Chair:

Richard Stone, MD
Dana-Farber Cancer Institute
Boston, MA, United States

Speakers:

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Jeffrey Lancet, MD
H. Lee Moffitt Cancer Center
Tampa, FL, United States

Roland Walter, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Contact:

Charlene Foroutan
Email: cforoutan@medscape.net

back to top